1. Home
  2. VNO vs IMVT Comparison

VNO vs IMVT Comparison

Compare VNO & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vornado Realty Trust

VNO

Vornado Realty Trust

HOLD

Current Price

$38.40

Market Cap

6.3B

Sector

Real Estate

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$31.16

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VNO
IMVT
Founded
1946
2018
Country
United States
United States
Employees
3145
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
5.8B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
VNO
IMVT
Price
$38.40
$31.16
Analyst Decision
Hold
Buy
Analyst Count
10
8
Target Price
$33.00
$33.00
AVG Volume (30 Days)
1.5M
2.3M
Earning Date
05-04-2026
05-28-2026
Dividend Yield
2.52%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.42
N/A
P/E Ratio
$7.08
N/A
Revenue Growth
N/A
N/A
52 Week Low
$24.57
$14.32
52 Week High
$43.37
$36.29

Technical Indicators

Market Signals
Indicator
VNO
IMVT
Relative Strength Index (RSI) 80.75 51.92
Support Level $38.07 $22.84
Resistance Level $40.49 $36.29
Average True Range (ATR) 1.03 1.97
MACD 0.40 -0.32
Stochastic Oscillator 96.13 16.17

Price Performance

Historical Comparison
VNO
IMVT

About VNO Vornado Realty Trust

Vornado Realty Trust is a fully integrated real estate investment trust with a portfolio of New York City office, retail, and multifamily assets, and the developer of the new Penn District. While concentrated in New York, the trust also owns assets in both Chicago and San Francisco. It generates revenue in the form of property rentals, fees charged for trade shows, parking revenues, management and leasing fees, etc. Vornado operates in the following reportable segments: New York (its key revenue-generating market) and Other.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Share on Social Networks: